deferoxamine has been researched along with Cancer of Prostate in 17 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment-induced neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer." | 1.72 | Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. ( Chakraborty, G; Chen, Y; Gutierrez, JA; Kalidindi, TM; Khitrov, S; Korsen, JA; Lewis, JS; Morris, MJ; Pillarsetty, N; Poirier, JT; Rudin, CM; Samuels, ZV, 2022) |
| "PC-3 prostate cancer cells were used in this study." | 1.38 | Impact of JNK1, JNK2, and ligase Itch on reactive oxygen species formation and survival of prostate cancer cells treated with diallyl trisulfide. ( Antosiewicz, J; Borkowska, A; Fedeli, D; Herman-Antosiewicz, A; Jozwik, A; Sielicka-Dudzin, A; Wozniak, M, 2012) |
| "We used as a model human prostate cancer cells, DU145." | 1.34 | Tumor necrosis factor-alpha-induced reactive oxygen species formation is mediated by JNK1-dependent ferritin degradation and elevation of labile iron pool. ( Antosiewicz, J; Herman-Antosiewicz, A; Kaczor, JJ; Ziolkowski, W, 2007) |
| "Using DU145 and PC-3 human prostate cancer cells as a model, we now report a novel mechanism involving c-Jun NH(2)-terminal kinase (JNK) signaling axis, which is known for its role in regulation of cell survival and apoptosis, in DATS-induced ROS production." | 1.33 | c-Jun NH(2)-terminal kinase signaling axis regulates diallyl trisulfide-induced generation of reactive oxygen species and cell cycle arrest in human prostate cancer cells. ( Antosiewicz, J; Herman-Antosiewicz, A; Marynowski, SW; Singh, SV, 2006) |
| "We tested non-hematopoietic human tumors for in vitro sensitivity to either a pair of synergistic IgG antitransferrin (Tf) receptor monoclonal antibodies (MAbs), deferoxamine (DFO) or the combination thereof." | 1.29 | Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro. ( Kemp, JD; Kovar, J; Naumann, PW; Stewart, BC, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Korsen, JA | 1 |
| Kalidindi, TM | 1 |
| Khitrov, S | 1 |
| Samuels, ZV | 1 |
| Chakraborty, G | 1 |
| Gutierrez, JA | 1 |
| Poirier, JT | 1 |
| Rudin, CM | 1 |
| Chen, Y | 1 |
| Morris, MJ | 1 |
| Pillarsetty, N | 1 |
| Lewis, JS | 5 |
| Noor, A | 1 |
| Van Zuylekom, JK | 1 |
| Rudd, SE | 1 |
| Waldeck, K | 1 |
| Roselt, PD | 1 |
| Haskali, MB | 1 |
| Wheatcroft, MP | 1 |
| Yan, E | 1 |
| Hicks, RJ | 1 |
| Cullinane, C | 1 |
| Donnelly, PS | 1 |
| Fukuhara, H | 1 |
| Inoue, K | 1 |
| Kurabayashi, A | 1 |
| Furihata, M | 1 |
| Fujita, H | 1 |
| Utsumi, K | 1 |
| Sasaki, J | 1 |
| Shuin, T | 1 |
| Zeglis, BM | 1 |
| Ruggiero, A | 1 |
| Holland, JP | 3 |
| Grimm, J | 1 |
| Heneweer, C | 1 |
| Divilov, V | 1 |
| Carlin, S | 1 |
| Sielicka-Dudzin, A | 1 |
| Borkowska, A | 1 |
| Herman-Antosiewicz, A | 3 |
| Wozniak, M | 1 |
| Jozwik, A | 1 |
| Fedeli, D | 1 |
| Antosiewicz, J | 3 |
| Evans, MJ | 1 |
| Rice, SL | 1 |
| Wongvipat, J | 1 |
| Sawyers, CL | 1 |
| Minchenko, O | 1 |
| Opentanova, I | 1 |
| Minchenko, D | 1 |
| Ogura, T | 1 |
| Esumi, H | 1 |
| Juang, HH | 1 |
| Ranney, D | 1 |
| Antich, P | 1 |
| Dadey, E | 1 |
| Mason, R | 1 |
| Kulkarni, P | 1 |
| Singh, O | 1 |
| Chen, H | 1 |
| Constantanescu, A | 1 |
| Parkey, R | 1 |
| Marynowski, SW | 1 |
| Singh, SV | 1 |
| Ziolkowski, W | 1 |
| Kaczor, JJ | 1 |
| White, SJ | 1 |
| Kasman, LM | 1 |
| Kelly, MM | 1 |
| Lu, P | 1 |
| Spruill, L | 1 |
| McDermott, PJ | 1 |
| Voelkel-Johnson, C | 1 |
| Kovar, J | 1 |
| Naumann, PW | 1 |
| Stewart, BC | 1 |
| Kemp, JD | 2 |
| Dreicer, R | 1 |
| Stegink, LD | 1 |
| Cardillo, T | 1 |
| Davis, CS | 1 |
| Forest, PK | 1 |
| See, WA | 1 |
| Lee, GR | 1 |
| Cartwright, GE | 1 |
| Wintrobe, MM | 1 |
1 trial available for deferoxamine and Cancer of Prostate
| Article | Year |
|---|---|
A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Creatinine; Deferoxami | 1997 |
16 other studies available for deferoxamine and Cancer of Prostate
| Article | Year |
|---|---|
Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3.
Topics: Animals; Carcinoma, Neuroendocrine; Cell Line, Tumor; Deferoxamine; Gallium Isotopes; Gallium Radioi | 2022 |
Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Cell Transformation, Neoplastic; Deferoxamine; Enzyme | 2020 |
The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Cell Line, Tumor; Chloroquine; Deferoxamine; Drug Synergism | 2013 |
The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Deferoxamine; Heterografts; Humans; Immunoconjuga | 2015 |
Cerenkov luminescence imaging of medical isotopes.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Beta Particles; Deferoxamine; Diagnostic Imaging; | 2010 |
Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system.
Topics: Animals; Autoradiography; Deferoxamine; Drug Stability; Humans; Image Processing, Computer-Assisted; | 2011 |
Impact of JNK1, JNK2, and ligase Itch on reactive oxygen species formation and survival of prostate cancer cells treated with diallyl trisulfide.
Topics: Allyl Compounds; Cell Line, Tumor; Cell Survival; Comet Assay; Deferoxamine; DNA Damage; Ferritins; | 2012 |
Annotating MYC status with 89Zr-transferrin imaging.
Topics: Animals; Deferoxamine; Male; Mice; Mice, Transgenic; Positron-Emission Tomography; Prostatic Intraep | 2012 |
Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation.
Topics: Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cobalt; Deferoxamine; Enzyme Induction; E | 2004 |
Modulation of iron on mitochondrial aconitase expression in human prostatic carcinoma cells.
Topics: Aconitate Hydratase; Adenosine Triphosphate; Ascorbic Acid; Base Sequence; Cell Line, Tumor; Cell Pr | 2004 |
Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Carbohydrate Sequen | 2005 |
c-Jun NH(2)-terminal kinase signaling axis regulates diallyl trisulfide-induced generation of reactive oxygen species and cell cycle arrest in human prostate cancer cells.
Topics: Allyl Compounds; Cell Cycle; Cell Division; Cell Line, Tumor; Deferoxamine; Ferritins; G2 Phase; Hum | 2006 |
Tumor necrosis factor-alpha-induced reactive oxygen species formation is mediated by JNK1-dependent ferritin degradation and elevation of labile iron pool.
Topics: Cell Line; Deferoxamine; Ferritins; Humans; Iron; Male; Mitogen-Activated Protein Kinase 8; Prostati | 2007 |
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Cycle; Cell Line, Tumor; Deferoxam | 2007 |
Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro.
Topics: Antibodies, Monoclonal; Breast Neoplasms; Deferoxamine; Down-Regulation; Female; Humans; Male; Neopl | 1995 |
The response of free erythrocyte protoporphyrin to pyridoxine therapy in a patient with sideroachrestic (sideroblastic) anemia.
Topics: Aged; Anemia; Blood Sedimentation; Deferoxamine; Erythrocytes; Hemoglobins; Humans; In Vitro Techniq | 1966 |